Company intelligence / Profile preview

PhotonPharma

Fort Collins, Colorado, United Statesphotonpharmaceuticals.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

PhotonPharma’s lead program Innocell™ has received FDA clearance for a Phase 1 clinical study in patients with recurrent epithelial ovarian cancer. The trial will assess safety and immunogenicity. Preclinical studies have demonstrated efficacy and safety in animal models. No human efficacy data yet available as of May 2025.

Therapeutic areas: Oncology
Modalities: Autologous cell therapycancer vaccine (autologous tumor cell-based immunotherapy)
Industry: Biotech

Drug pipeline

1 asset

Innocell

Partnerships

Collaboration with Colorado State University for preclinical researchCity of Hope mentioned as a collaborator during CEO transition announcement

Beyond the preview

Go deeper on PhotonPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PhotonPharma.

Explore the full profile